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The serotype-specific Mprotein emanating as a-helical coiled-coil fibrils from
the surface of Streptococcus pyogenes is the major virulence determinant of these
organisms (1-2). The fibrinogen binding and antiopsonic properties of these
fibrils is overcome only by type-specific antibodies directed against epitopes of
Mprotein not masked by fibrinogen (3-7). In addition to the protective epitopes,
certain M proteins contain autoimmune epitopes that can evoke immune re-
sponses against host tissues, especially cardiac tissue (8-12) . Because the nonsup-
purative sequela of streptococcal infections, acute rheumatic heart disease, is
manifested by damage to cardiac tissues, efforts have been made to avoid these
epitopes in M protein vaccine preparations. Our approach has been to synthesize
peptide copies of selected regions of various M proteins in an attempt to devise
protective vaccines free of autoimmune epitopes (13-14). In this way, we have
shown that the NH2-termini of types 5 and 6 Mproteins contain protective, but
not tissue crossreactive, epitopes (15, 16). One problem with the approach has
been the high degree of type specificity of the highly variable NH2-terminal
sequences ofthese M proteins. In an attempt to overcome this problem, we have
begun synthesizing short peptide sequences of different serotypes of M protein
in tandem, with the hope that the tandem hybridswould evoke broadlyprotective
immunity against many serotypes ofS. pyogenes (17) .
Recently, we reported (17) the protective immunogenicity ofa bivalent peptide
containing the NH2-terminal sequence oftype 5 M protein synthesized in tandem
with the COOH-terminal sequence ofcyanogen bromide fragment seven (CB7)'
of type 24 M protein. In this paper, we report the type-specific protective
immunogenicity of a trivalent peptide copying the NH2-terminal sequences of
types 5, 6, and 24 M proteins synthesized in tandem. We show that the trivalent
hybrid linked via a COOH-terminal cysteine residue to keyhole lympet hemo-
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cyanin (KLH) evokes high titers of antibodies against each of the respective
natural M protein serotypes . The immune sera are shown to opsonize all three
serotypes of streptococci and to lack tissue crossreactive antibodies. Moreover,
the trivalent peptide is shown to sensitize rabbit T lymphocytes to respond to
each of the natural M proteins as well as the synthetic, trivalent peptide. These
findings have bearing on the construction of safe and effective vaccines against
a variety of different serotypes of S. pyogenes, especially against the strains that
trigger acute rheumatic fever and rheumatic heart disease.
Material and Methods
Natural and Synthetic Polypeptides ofStreptococcal M Proteins.
￿
Polypeptide fragments of
M proteins were isolated and purified from limited peptide digests of types 5, 6, and 24
streptococci as described (18, 19). The polypeptides designated pep M5, pep M6, and pep
M24 were judged to be pure by SDS-PAGE and quantitative amino acid analysis (20).
Synthetic copies of the NH2-terminal ends of types 5, 6, and 24 M proteins were
synthesized separately and in tandem by the solid-phase method of Merrifield (21) as
described (15). A COON-terminal cysteine residue was added to each peptide for the
purpose of coupling to carriers. The synthetic peptides were purified by gel filtration on
columns of Sephadex G50, and further purified as needed by reverse-phase HPLC on
Ultrasphere ODS (Whatman Inc., Clifton, NJ) (15). The purified peptides were analyzed
for purity and composition by quantitative amino acid analysis and automated Edman
degradation to the penultimate amino acid residues (14, 22). The monovalent synthetic
peptides are designated SM5(1-10)C, SM6(1-11)C, and SM24(1-12)C. The tandem peptide
is designated SM5(1-10)-SM6(1-11)-SM24(1-12)C or SM5-6-24C.
Rabbit Immunization.
￿
Sets ofthree New Zealand White rabbits (2 kg) were each injected
with a 50-nmol dose of the trivalent peptide SM5-6-24, either in the unconjugated state
or conjugated to KLH using succinimidyl 4-(N-maleimido-methyl)-cyclohexame-l-carbox-
ylate (Pierce Chemical Co., Rockford, I L) and emulsified in CFA as described (23). Rabbits
were bled before, and at 2-wk intervals after the primary immunizing dose. At 4, 8, and
10 wk, each rabbit was injected with a 50 nmol s.c. booster dose of the same peptide
preparation in PBS (0.02 M phosphate with 0.15 M NaCl, pH 7 .4). All sera were heat
inactivated at 56°C for 30 min and stored in sterile vials at 4°C.
Assays ofAnti-M Protein Antibodies.
￿
The rabbit sera were assayed for antibodies against
M protein by ELISA and opsonophagocytic assays as described (24). The serotype
specificity of the antibodies raised against the hybrid peptide was determined by ELISA
and phagocytosis inhibition studies, using each of the serotypes of whole streptococci as
absorbents or the monovalent or trivalent peptides as soluble inhibitors. The antisera (0.1
ml) were mixed with an equal volume of washed whole streptococci, incubated for 30 min
at 37°C, and centrifuged at 12,000 g for 15 min to remove the bacteria. The absorbed
sera were then used in opsonophagocytosis tests against types 5, 6, and 24 streptococci.
The antisera (0.1 ml) were similarly incubated with 100 uM synthetic peptide, and after
incubation for 30 min at 37°C, the mixtures were used in the opsonophagocytosis tests.
Lymphocyte Cultures.
￿
Mononuclear cells were isolated from whole, heparinized (100
U/ml) rabbit blood by Ficoll-Hypaque gradient centrifugation, washed three times,
counted, and resuspended in RPMI 1640 (Grand Island Biological Co., Grand Island,
NY) supplemented with penicillin (100 U/ml), streptomycin (100 ug/ml), t.-glutamine (2
mM), and Hepes buffer (25 mM). Cells (2 X 105) were cultured in 96-well round-bottomed
tissue culture plates (No. 3799; Costar, Cambridge, MA) in a total volume of 200 ul RPMI
1640 supplemented with 5% heat-inactivated FCS (Grand Island Biological Co.). Cells
were incubated with pep M proteins or KLH at concentrations of 10 jug/ml or with 10
nmol synthetic peptides that had been dried onto the wells in sterile distilled water before
the experiments (25). The cells were cultured for 5 d at 37°C. 6 h before harvesting, 1
ACi of ['H]thymidine (sp act 2 Ci/mmol ; Research Products International Corp., Prospect,
II) in 25 ul of culture medium was added to each well . Cultures were harvested with a5
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FIGURE 1 .
￿
Amino acid sequence of
trivalent M protein peptide .
multiple automated sample harvester, and the samples were counted for 4 min each in a
liquid scintillation counter .
Results
We synthesized a trivalent hybrid peptide copying the NH 2-terminal 10 resi-
dues of pep M5, 11 residues of pep M6, and 12 residues of pep M24 . The
composition of the hybrid peptide was confirmed by quantitative amino acid
analysis . Sequence analysis by Edman degradation to the penultimate residues
confirmed the sequence as shown in Fig . 1 .
The hybrid peptide is designated as SM5(1-10)-SM6(1-11)-SM24(1-12)C or
SM5-6-24C . The COOH-terminal cysteine residue was added for the purpose of
coupling to a carrier. The composition of the additional monovalent peptides
SM5(1-10)C, SM6(1-11)C, SM24(1-12)C were similarly confirmed by amino acid
analysis . These synthetic peptides were used in the following studies .
Immunogenicity of Trivalent Peptide SM5-6-24C.
￿
Immunization of rabbits with
SM5-6-24C covalently linked through its COOH-terminal cysteine residue to
KLH evoked high titers of antibodies against the respective M proteins as
measured by ELISA using pep M5, pep M6, or pep M24 as antigens (Table 1) .
Four of the seven immunized rabbits produced antibodies against all three M
proteins . ELISA inhibition experiments demonstrated that the hybrid peptide
inhibited all of the antibody reactivities with pep M5, pep M6, or pep M24 (Fig .
2) . The subpeptides SM5(1-10)C, SM6(1-11)C, and SM24(1-12)C completely
inhibitedthe reactivity of the anti-SM5-6-24C serum only againstthe homologous
serotype of pep M protein, although the highest concentration of SM5(1-10)C
tested partially inhibited reactivity of the antiserum with pep M6 (Fig . 2) .
The antisera raised against the trivalent hybrid peptide opsonized and killed
types 5, 6, and 24 streptococci (Tables II and 111) . Four of the seven antisera
opsonized all three serotypes, although the opsonization of type 5 streptococci
by rabbit serum 8593 was weak, as demonstrated both by phagocytosis (Table
11) and indirect bactericidal tests (Table III) . All opsonized type 6 and all except
one opsonized type 24 streptococci . The type specificity of the opsonic antibodies
was demonstrated by opsonization inhibition tests (Table IV) . Absorption of the
antisera with the respective serotypes of whole streptococci removed only the
opsonic antibodies against the homologous serotype . Similarly, each of the65 0
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* The preimmune sera from each of the rabbits gave titers of <200 against each of the antigens
tested in ELISA. The endpoint in each case is recorded as the reciprocal of the highest dilution of
antiserum producing an absorbance reading ?0.1 at 450 nm. Because dilutions of each of the
antisera resulted in absorbancy curves that fell sharply (data not shown), indicating antibodies of
high affinity, the endpoint value used was considered to be valid.
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TABLE I
ELISA ofSera ofRabbits Immunized with SM5-6-24C
Conjugated to KLH and Emulsified in CFA
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CONCENTRATION OF INHIBITING PEPTIDE, pM
FIGURE 2.
￿
Inhibition of the reactions ofanti-SM5-6-24C with immobilized pepM5 (left), pep
M6 (middle), and pep M24 (right) by the component peptides SM5(1-10)C, SM6(1-1I)C, and
SM24(1-12)C and the trivalent hybrid peptide SM5-6-24C. Note that the hybrid peptide
inhibited the reactions against each of the pep M proteins whereas the component peptides
inhibited only the homologous reactions. The exception was thepartial inhibition by SM5(1-
10)C of thereaction ofanti-SM5-6-24C with pep M6 (middle).
synthetic subpeptides inhibited only the opsonic antibodies against the organisms
bearing the parent serotype of M protein. The hybrid peptide inhibited opsoni-
zation of all three serotypes (Table IV).
Absence ofAutoimmune Epitopes in SM5-6-24C.
￿
Because types 5 and 6 pep M
proteins were previously shown to contain host tissue crossreactive epitopes (9-
11), we examined the synthetic hybrid peptide for such epitopes. The trivalent
hybrid peptide failed to inhibit the cardiac sarcolemmal and myosin crossreactive
antibodies in any of the antisera previously raised (9-11) against types 5 and 6
M proteins. Moreover, none of the seven rabbits developed antibodies that
crossreacted with human myocardium, as measured by immunofluorescence tests
of frozen sections of human cardiac tissue, or myosin, as measured by ELISA or
Immune sera,
rabbit number pep M5
ELISA
pep M6
titers against:
pep M24 SM5-6-24C
Preimmune* <200 <200 <200 <200
8507 25,600 51,200 51,200 >102,400
8508 3,200 400 25,600 51,200
8509 200 6,400 12,800 52,200
8591 51,200 102,400 51,200 102,400
8592 200 6,400 200 25,600
8593 6,400 51,200 25,600 51,200
8594 <200 102,400 400 >102,400TABLE II
Opsonic Antibodies in Sera ofRabbits Immunized with SM5-6-24C
Conjugated to KLH and Emulsified in CFA
BEACHEY ET AL.
* Immune sera were obtained 1 wk afteran initial injection of 50 nmol of
SM5-6-24Cemulsified in CFAfollowed by boosterinjections ofthesame
dose in PBS at 4 and 8 wk. The type specificity of the M5-M6-M24
hybrid peptide was confirmed by the failure of the immune sera to
promote phagocytosis and killing of heterologous types 1, 12, and 19
streptococci.
The preimmune pool contained equal amounts of sera obtained from
each of therabbits before immunization.
TABLE III
Indirect Bactericidal Tests ofSera ofRabbits Immunized with
SM5-6-24C Hybrid Peptide
651
Western immunoblots (data not shown). These results indicate that the NH2-
terminal regions ofeach of the M proteins incorporated into the tandem hybrid
peptide contained protective but not autoimmune epitopes.
Cell-mediated Immune Responses in Rabbits Immunized with SM5-6-24C.
￿
Pre-
vious studies (13) have shown that synthetic peptide copies of M proteins are
capable of priming lymphocytes in vivo to respond to subsequent in vitro
challenge with the natural pep Mproteins. In the present study, it was ofinterest
to determine if the synthetic hybrid peptide had the ability to mimic T cell
epitopes of the corresponding natural M proteins. Preimmune and immune (10
wk) lymphocytes were cultured in the presence of 10 lag/ml of KLH or pep M
Immune sera,*
rabbit number
Opsonization: neutrophils with
associated streptococci
Type 5 Type 6 Type 24
Preimmunepool* 4 2 0
8507 82 80 96
8508 44 62 92
8509 0 88 84
8591 66 86 78
8592 2 84 2
8593 38 82 72
8594 4 84 88
Number ofcolonies of streptococci
Immune sera,
rabbit number
after 3
Type 5
(Inoculum 9)
h growth in test
Type 6
(Inoculum 13)
mixtures
Type 24
(Inoculum 13)
Preimmunepool 2,020 3,554 2,200
8507 20 115 760
8508 155 250 560
8509 2,140 190 400
8591 490 485 15
8592 2,090 185 2,360
8593 1,010 90 195
8594 2,100 95 240652
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TABLE IV
Specificity of Opsonic Antibodies Raised in Rabbits Against
SM5-6-24C Trivalent Hybrid Peptide
TABLE V
In Vitro Blastogenic Responses ofLymphocytesfrom Rabbits Immunized with Synthetic
Hybrid Vaccine SM5-6-24C-KLH
* Immune lymphocytes were collected and cultured in vitro as described in Materials and Methods. Unstimulated control cultures were
incubated without antigen.
proteins in solution, or 10 nmol of unconjugated synthetic peptides that had
been dried onto plastic plates (25). Immune lymphocytes from all three rabbits
showed significant blastogenesis in response to in vitro challenge with all three
pep M proteins, as measured by [3H]thymidine incorporation (Table V). The
lymphocytes of one of three rabbits (8663) responded to the hybrid synthetic
peptide, whereas none responded to the individual component peptides (Table
IV). Taken together, these results suggest that the hybrid peptide can prime
lymphocytes in vivo to respond to epitopes of the natural M proteins in addition
to the hybrid synthetic immunogen. The inability of the individual synthetic
peptides to stimulate lymphocyte blastogenesis may relate to their molecular size,
conformation, or mode of presentation . To test the latter hypothesis, each
Streptococci
opsonized with:
Opsonization: neutrophils
with associated streptococci
Type 5 Type 6 Type 24
Preimmune serum 2 4 2
Anti-SM5-6-24C 76 78 74
Absorbed with:
Type 5 streptococci 0 78 72
Type 6 streptococci 74 6 70
Type 24 streptococci 78 76 2
Inhibited with:
SM5(1-10) C 0 76 72
SM6(1-11) C 78 6 76
SM24(1-12) C 78 76 2
SM5-6-24 C 0 6 4
Lymphocytes
cpm [sH]thymidine incorporation ±SEMinto lymphocytes from rabbit number:
stimulated 8662 8663 8665
with:*
Preimmune 10 wk Preimmune 10 wk Preimmune 10 wk
Control 614 t 99 859 t 62 165 ± 74 2,036 t29 1,068 t243 2,132 ± 210
KLH 445 ± 43 2,673 t 6,437 380 t81 80,452 t6,040 1,353 t224 48,453 ± 3,660
pep M5 5,969 t 147 110,851 ± 18,324 3,385 t 136 212,640 t7,450 7,083 t353 72,272 t 467
pep M6 6,706 i 745 26,488 t 1,319 2,714 ±249 37,897 t2,748 1,536 t 197 6,225 t 397
pep M24 2,611 ± 242 7,841 ± 830 3,658 t 133 19,780 t2,363 5,262 t 1,453 14,642 t 3,222
SM5-6-24C 407 t 150 857 t 86 328 t71 28,593 t6,814 1,134 t537 3,175 t 850
SM5(1-10) C 563 t 70 643 t 197 424 t 24 615 t81 419 t61 1,441 t 321
SM6(1-11) C 311 ± 88 530 t 226 217 t42 1,787 ±616 343 t58 824 t 70
SM24(1-12)(: 663 t 66 473 t 119 342 t66 3,885 t 1,214 522 t 120 1,017 t 396BEACHEY ET AL.
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peptide was covalently coupled to BSA and presented to theimmune lymphocytes
in solution. Under theseconditions, lymphocytesfrom allthreerabbits responded
to the hybrid peptide, but none responded to the individual component peptides
(data not shown), suggesting that the subpeptides were incapable of taking on
the conformation required to stimulate T lymphocytes sensitized with the trihy-
brid peptide.
Discussion
It has previously been reported (17, 26) that peptide copies of virulent
determinants of bacteria synthesized in tandem are capable of evoking immune
responses against the natural protein. Houghten et al . (26) reported that peroral
administration of a hybrid peptide containing a 26-amino-acid-residue copy of
the labile toxinjoined in tandem to an 18-residue copy of stable toxin stimulated
protective immune responses against both the heat-labile and heat-stable toxins
of Escherichia coli. Recently, Beachey et al. (17) demonstrated that a 20-residue
NH2-terminal peptide of type 5 M protein synthesized in tandem with a 13-
residue peptide of type 24 M protein evoked opsonic antibodies against the
respective serotypes of streptococci. However, to our knowledge, the present
study is the first to show that a tandem peptide containing more than two distinct
virulence determinants is capable of stimulating immune responses to each of
the respective natural proteins on the surface of virulent microorganisms. The
question as to whether a short peptide flanked on each end by different peptides
containing distinctly different immunospecificities would be seen in a natural
conformation by the immune system is of some practical concern as well as of
theoretical importance. Our studies clearly demonstrate that an 11-residue
peptide of type 6 M protein, flanked on its NH2-terminal end by a 10-residue
peptide of type 5 M protein and on its COOH-terminal end by a 12-residue
peptide of type 24 M protein, is readily recognized by the immune system in the
rabbit. In fact, the antibody responses as measured by opsonization of the
respective serotypes were universal to the type 6 peptide; all of the rabbits
immunized with the trivalent hybrid peptide developed opsonic antibodies
against type 6 streptococci, whereas only four of seven developed antibodies
against type 5 streptococci and six of seven against type 24 organisms. Thus, the
potentially hidden position of the middle peptide in this case was not a detriment
to recognition.
It should be noted that the type 5 peptide contains a proline residuejoined to
the NH2-terminal arginine residue of the type 6 peptide, and that, in turn, the
type 6 peptide contains a proline residue joined to the NH2-terminal valine
residue of type 24 M protein. Because proline residues are known to be strong
helix breakers, the central part of the molecule theoretically should be consid-
erably more mobile, permitting the exposure of the M6 epitopes in the confor-
mationsrequired for recognition by the immune system as epitopes of the natural
protein from which it was derived.
Our previous studies of a bivalent hybrid peptide of types 5 and 24 M proteins
(17) demonstrated that the peptides were equally immunogenic with respect to
the antibodies evoked against the natural protein, whether or not attempts were
made to preserve the secondary structural potentials of the original proteins.654
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The present studies provide additional evidence that strict conservation of the
secondary and tertiary structural features of the original proteins is not the key
to protective immunogenicity of small peptidecopies of streptococcal M proteins.
It should be noted that the peptides copied in the trivalent hybrid represent
the NH2-termini of types 5, 6, and 24 M proteins. Although the NH2-terminal
peptides of types 5 and 6 M proteins had previously been demonstrated to
stimulate type-specific protective immune responses, these are the first studies to
show similar protective properties of the NH2-terminus of type 24 M protein.
The region of type 24 M protein contained in the bivalent hybrid peptide
previously reported from our laboratories (17) was a copy of the COOH-terminal
13 residues of CB7, an internal peptide fragment that is repeated five times in
the M protein molecule (14). The presence of this repeating peptide may have
accounted for the greater immunogenicity of the bivalent hybrid in the uncon-
jugated form ; the trivalent peptide reported in the present study was less
immunogenic without conjugation to a carrier protein.
The generic implications of these studies is that one may selectively engineer
a multivalent peptide vaccine containing protective epitopes of a variety of
infectious agents . Although multivalent vaccine preparations have been made by
polymerization of several synthetic peptides to each other with glutaraldehyde
(27), this approach raises problems of potential toxicities associated with the
polymerizing agent. Furthermore, the orientation and accessibility of protective
epitopes is less predictable in such polymers. The tandem peptide approach has
the advantage that one may tailor vaccine preparations that expose protective
epitopes in a predictable and optimally immunoaccessible fashion.
Our studies clearly demonstrate that the hybrid M protein peptide is capable
ofprimingT lymphocytes to respond to each of the respective natural M proteins
as well as to the hybrid peptide itself in vitro. The failure of the individual
component peptides to stimulate the primed lymphocytes either unconjugated
or conjugated to BSA suggests that in the isolated state, they were unable to take
on the conformation needed for recognition by the sensitized T cells. It appears,
therefore, that the hybrid peptide confers structural features upon each of the
component peptides more nearly resembling their presentations in the respective
natural M proteins.
Summary
The protective immunogenicity of a hybrid peptide containing tandem copies
of types 5, 6, and 24 M protein epitopes was investigated. An NH2-terminal
peptide of type 24 M protein was chemically synthesized and then extended to
include NH2-terminal peptides of types 6 and 5 M proteins yielding a 34-residue
hybrid peptide containing a cysteine residue at its COOH-terminus. When
conjugated via the cysteine residue to keyhole limpet hemocyanin (KLH), emul-
sified in CFA, and injected into rabbits, the synthetic hybrid evoked opsonic
antibodies against types 5, 6, and 24 streptococci without stimulating tissue
crossreactive immunity. The trivalent hybrid also was capable of priming T
lymphocytes in vivo that responded to each of the native serotypes of M protein
as well as to the synthetic hybrid peptide in vitro. The primed T cells failed to
respond to the individual component peptides contained in the hybrid peptide,BEACHEY ET AL.
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suggesting that the hybrid peptide confers conformations resembling the pres-
entations of each of the subpeptides in the respective serotypes of M protein.
The brisk immune responses to the type 6 peptide contained in the middle of
the tandem hybrid indicates that with judicious placement between proline
residues, potentially hidden peptides are readily accessible to the immune system.
These results suggest that synthetic tandem peptides can be tailored in a fashion
in which each of the component sets ofprotective epitopes can be made optimally
immunoaccessible and immunogenic.
We thank Edna Chiang, Carolyn Costlow, Dan Monroe, Quinn Cain, and Bob Cassel for
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